Pharmacoeconomic analysis of clinical efficiency of combined metformin (Siofor) - insulin therapy in patients with type 2 diabetes mellitus

Aim. To assess expedience of metformin combination with long-acting insulin, determine optimal doses of metformin for patients with type 2 diabetesmellitus (DM2), and accomplish pharmacoeconomic analysis of clinical efficiency of various therapeutic modalities. Materials and methods. Patients with...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	I Yu Demidova, T V Gorokhova, Yu B Belousov, D Yu Belousov
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2009
Materias:	metformin insulin therapy combined therapy pharmacoeconomic analysis Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/dbec75fcad3644aea6b212d3ed27879b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dbec75fcad3644aea6b212d3ed27879b
record_format	dspace
spelling	oai:doaj.org-article:dbec75fcad3644aea6b212d3ed27879b2021-11-14T09:00:13ZPharmacoeconomic analysis of clinical efficiency of combined metformin (Siofor) - insulin therapy in patients with type 2 diabetes mellitus2072-03512072-037810.14341/2072-0351-5401https://doaj.org/article/dbec75fcad3644aea6b212d3ed27879b2009-06-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/5401https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Aim. To assess expedience of metformin combination with long-acting insulin, determine optimal doses of metformin for patients with type 2 diabetesmellitus (DM2), and accomplish pharmacoeconomic analysis of clinical efficiency of various therapeutic modalities. Materials and methods. Patients with decompensated DM2 (n=126) were under observation for 1 year during which they received rational hypoglycemictherapy with metformin and long-acting insulin (LAI) at bedtime, with the dose being titrated until the desired level of glycemic control wasachieved. The patients were randomly allocated to the following 3 groups: group 1 (sulponylurea derivatives (SUD), LAI, and metformin at a doseof 1000 mg b.i.d.), group 2 (SUD, LAI, and metformin at 500 mg b.i.d.), group 3 (SUD and LAI). In case of postprandial glycemia >9 mmol/l at amaximum dose of SUD, it was replaced by short-acting insulin. Cost-effectiveness analysis of different therapeutic regimes was performed. Results. The cost of examination and treatment of patients given SUD and LAI in combination with metformin at a daily dose of 2000 mg to achievethe desired quality of glycemic control was lower compared with two other groups. Moreover, this therapy was most efficacious and ensured the desiredlevel of glycemic control in a greater number of patients. Cost-effectiveness analysis confirmed advantages of this treatment. Conclusion. Combined hypoglycemic therapy with SUD, LAI, and metformin (200 mg daily) has the advantage of lowest cost and maximum efficiencycompared with other modalities.I Yu DemidovaT V GorokhovaYu B BelousovD Yu BelousovEndocrinology Research Centrearticlemetformininsulin therapycombined therapypharmacoeconomic analysisNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 12, Iss 2, Pp 63-66 (2009)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	metformin insulin therapy combined therapy pharmacoeconomic analysis Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	metformin insulin therapy combined therapy pharmacoeconomic analysis Nutritional diseases. Deficiency diseases RC620-627 I Yu Demidova T V Gorokhova Yu B Belousov D Yu Belousov Pharmacoeconomic analysis of clinical efficiency of combined metformin (Siofor) - insulin therapy in patients with type 2 diabetes mellitus
description	Aim. To assess expedience of metformin combination with long-acting insulin, determine optimal doses of metformin for patients with type 2 diabetesmellitus (DM2), and accomplish pharmacoeconomic analysis of clinical efficiency of various therapeutic modalities. Materials and methods. Patients with decompensated DM2 (n=126) were under observation for 1 year during which they received rational hypoglycemictherapy with metformin and long-acting insulin (LAI) at bedtime, with the dose being titrated until the desired level of glycemic control wasachieved. The patients were randomly allocated to the following 3 groups: group 1 (sulponylurea derivatives (SUD), LAI, and metformin at a doseof 1000 mg b.i.d.), group 2 (SUD, LAI, and metformin at 500 mg b.i.d.), group 3 (SUD and LAI). In case of postprandial glycemia >9 mmol/l at amaximum dose of SUD, it was replaced by short-acting insulin. Cost-effectiveness analysis of different therapeutic regimes was performed. Results. The cost of examination and treatment of patients given SUD and LAI in combination with metformin at a daily dose of 2000 mg to achievethe desired quality of glycemic control was lower compared with two other groups. Moreover, this therapy was most efficacious and ensured the desiredlevel of glycemic control in a greater number of patients. Cost-effectiveness analysis confirmed advantages of this treatment. Conclusion. Combined hypoglycemic therapy with SUD, LAI, and metformin (200 mg daily) has the advantage of lowest cost and maximum efficiencycompared with other modalities.
format	article
author	I Yu Demidova T V Gorokhova Yu B Belousov D Yu Belousov
author_facet	I Yu Demidova T V Gorokhova Yu B Belousov D Yu Belousov
author_sort	I Yu Demidova
title	Pharmacoeconomic analysis of clinical efficiency of combined metformin (Siofor) - insulin therapy in patients with type 2 diabetes mellitus
title_short	Pharmacoeconomic analysis of clinical efficiency of combined metformin (Siofor) - insulin therapy in patients with type 2 diabetes mellitus
title_full	Pharmacoeconomic analysis of clinical efficiency of combined metformin (Siofor) - insulin therapy in patients with type 2 diabetes mellitus
title_fullStr	Pharmacoeconomic analysis of clinical efficiency of combined metformin (Siofor) - insulin therapy in patients with type 2 diabetes mellitus
title_full_unstemmed	Pharmacoeconomic analysis of clinical efficiency of combined metformin (Siofor) - insulin therapy in patients with type 2 diabetes mellitus
title_sort	pharmacoeconomic analysis of clinical efficiency of combined metformin (siofor) - insulin therapy in patients with type 2 diabetes mellitus
publisher	Endocrinology Research Centre
publishDate	2009
url	https://doaj.org/article/dbec75fcad3644aea6b212d3ed27879b
work_keys_str_mv	AT iyudemidova pharmacoeconomicanalysisofclinicalefficiencyofcombinedmetforminsioforinsulintherapyinpatientswithtype2diabetesmellitus AT tvgorokhova pharmacoeconomicanalysisofclinicalefficiencyofcombinedmetforminsioforinsulintherapyinpatientswithtype2diabetesmellitus AT yubbelousov pharmacoeconomicanalysisofclinicalefficiencyofcombinedmetforminsioforinsulintherapyinpatientswithtype2diabetesmellitus AT dyubelousov pharmacoeconomicanalysisofclinicalefficiencyofcombinedmetforminsioforinsulintherapyinpatientswithtype2diabetesmellitus
_version_	1718429683224150016

Pharmacoeconomic analysis of clinical efficiency of combined metformin (Siofor) - insulin therapy in patients with type 2 diabetes mellitus

Ejemplares similares